| Friday June 14 |
| 08:15-08:45 |
Registration and coffee |
| 08:45-09:00 |
Welcome and Introduction |
| |
|
| |
Session I |
Free Communications |
Chair: Pascal Girard |
| 09:00-09:20 |
Rudy Port |
Estimating individual pretreatment levels of a pharmacologic response variable |
| 09:20-09:40 |
Willi Weber |
Leflunomide population pharmacokinetics and its interaction with activated charcoal/cholestyramine |
| 09:40-10:00 |
M. Audran |
A population pharmacodynamics model of recombinant human erythropoietin in athletes |
| 10:00-10:20 |
Michel Tod |
Comparison of ED, EID, API and Bayesian-API criteria for the robust optimization of sampling times in pharmacokinetics |
| 10:20-11:00 |
Coffee Break, Poster Session I, Software Demonstrations |
| |
Session II |
Drug Development |
Chair: René Bruno |
| 11:00-11:30 |
Eliane Fuseau |
Population pharmacokinetics - an industrial viewpoint |
| 11:30-12:00 |
Janet Wade |
Presentation Of Population Analyses For Regulatory Submissions |
| 12:00-12:20 |
Mats Karlsson |
A population PK/PD model for the anti-Parkinsonian triple therapy: levodopa (LD), dopadecarboxylase (DDC) inhibitor and catechol-O-methyl transferase (COMT) inhibitor |
| 12:20-13:40 |
Lunch |
| |
|
|
|
| |
Session III |
Software I |
Chair: Ferdie Rombout |
| 13:40-14:10 |
Stuart Beal |
A preview of NONMEM version V |
| 14:10-14:15 |
Alison Thomson |
Short introduction to data set |
| 14:15-14:35 |
Niclas Jonsson |
Xpose |
| 14:35-15:05 |
Roberto Gomeni |
Visual NM |
| 15:05-15:50 |
Coffee break, Poster Session II, Software Demonstration |
| |
Session IV |
Software II |
Chair: Alain Mallet |
| 15:50-16:20 |
Guenther Strehlau |
POPKAN |
| 16:20-16:50 |
Pascal Girard |
P-Pharm |
| |
|
|
|
| 20:00-24:00 |
Social Evening |
|
| |
|
| |
| Saturday June 15 |
| |
Session V |
Methodology |
Chair: Jean-Louis Steimer |
| 09:00-09:45 |
Stuart Beal |
Simulating PK/PD trials |
| 09:45-10:30 |
France Mentré |
Optimal design in population pharmacokinetics |
| 10:30-11:15 |
Coffee break, Poster Session III, Software Demonstration |
| |
Session VI |
Methodology/Clinical Applications |
Chair: Willi Weber |
| 11:15-11:45 |
Pascal Girard |
A population markov model for analyzing dose history |
| 11:45-12:15 |
Pascal Maire |
Individualized Drug Therapy and Population Modeling |
| 12:15-12:35 |
Christian Pobel |
Neural network prediction of dose and pk parameters values from a population approach point of view |
| 12:35-12:55 |
Farkad Ezzet |
Inter-occasion variation in the bioavailability of Benflumetol (an anti malarial drug) |
| 12:55 |
Closing Statements |
POSTER SESSION I
- D. de Alwis, L. Aarons
The population pharmacokinetics of ondansetron: a covariate analysis
- F. Mentre, E. Comets, F. Pousset, B. Plaud, B. Diquet, G. Montalescot, A. Ankri, A. Mallet, Ph. Lechat
Population pharmacokinetics/pharmacodynamics of fluindione in patients
- D. Santos Buelga, M.J. Garcia Sanchez, A.C. Falcao, M.E. Mendez, A. Dominguez-Gil.
Population pharmacokinetics of tobramycin in neonates
- C. Pobel, D. Breilii, M.C. Saux, S. Demare, J.N. Parola
A population pharmacokinetic study of ciprofloxacine penetration into lung tissue
- M.L. McFadyen, M.P. Majola, R. Nair, M. Govender, H. Laher
The relationship of phenytoin concentrations to gingival hyperplasia
- Z. Hussein, C.J. Eaves, D.B. Hutchinson, C.J. Canfield
Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone
POSTER SESSION II
- R.C. Schoemaker, J. Burggraaf, A.F. Cohen
Assessment of liver blood flow using a continuous infusion of a drug with high hepatic clearance
- C. Laveille, F. Le coz, G. Lerebours, G. Resplandy, R. Jochemsen
Population pharmacokinetics of a new bradycardic agent in healthy male volunteers: influence of food and time of administration
- V. Piotrovskij, E. Snoek, A. van Peer
Liarozole population pharmacokinetics at the steady state
- T. Bouillon, D. Kietzmann, I. Meineke, R. Port, A. Hoeft
Pharmacokinetics of piritramide in patients undergoing elective surgery
- P.Milligan, M.Karlsson, D.Nichols
Experiences with CYP2D6 polymorphism in clinical drug development
- H. Schmid, G. Strehlau
Probability Statements about predicted kinetic/dynamic profiles in population analyses
POSTER SESSION III
- F. Ezzet
Population pharmacokinetics of Valsartan
- N.J. Bruce, A.H. Thomson, N. Undre, P. Stadler, H.L. Elliott
Assesment of Covariate Relationships in the Analysis of the Population Pharmacokinetics of Tacrolimus.
- M. Gardmark, M.O. Karlsson, M. Hammarlund-Udenaes
A pharmacodynamic model for morphine incorporating acute tolerance and M3G interactions
- L. Nguyen, G. Bastian, F. Doz, S. Urien, B. Peng, E. Chatelut, A.V. Boddy, D.R. Newell, H. Rubie, G. Houin, P. Canal
Prospective evaluation of a formula to predict carboplatin clearance in children
- S. Urien
MP2 (V2.0) A Windows application for population pharmacokinetics
- N.J. Rahman, J.C. Wakefield, C. Falcoz
Incorporation of population pharmacokinetic principles into drug development
